Evidence map›Paper›PMID 27499893›Full record

ArticleThe journal of pathology. Clinical research2015

High CerS5 expression levels associate with reduced patient survival and transition from apoptotic to autophagy signalling pathways in colorectal cancer.

Seán Fitzgerald, Katherine M Sheehan, Virginia Espina, Anthony O'Grady, Robert Cummins, Dermot Kenny, Lance Liotta, Richard O'Kennedy, Elaine W Kay, Gregor S Kijanka

Open access · hybridAbstract read
In one paragraph

Article in The journal of pathology. Clinical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. You aren't IMMUNE to the ceramides that accumulate in cardiometabolic disease.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Colon Cancer and Perturbations of the Sphingolipid Metabolism.International journal of molecular sciences · 2019
    Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Seán FitzgeraldBiomedical Diagnostics Institute, Dublin City UniversityDublinIreland; School of Biotechnology, Dublin City UniversityDublinIreland.
Katherine M SheehanDepartment of Pathology Royal College of Surgeons in Ireland and Beaumont Hospital Dublin Ireland.
Virginia EspinaCenter for Applied Proteomics and Molecular Medicine George Mason University Manassas VA USA.
Anthony O'GradyDepartment of Pathology Royal College of Surgeons in Ireland and Beaumont Hospital Dublin Ireland.
Robert CumminsDepartment of Pathology Royal College of Surgeons in Ireland and Beaumont Hospital Dublin Ireland.
Dermot KennyBiomedical Diagnostics Institute, Dublin City UniversityDublinIreland; Molecular and Cellular TherapeuticsThe Royal College of Surgeons in IrelandDublinIreland.
Lance LiottaCenter for Applied Proteomics and Molecular Medicine George Mason University Manassas VA USA.
Richard O'KennedyBiomedical Diagnostics Institute, Dublin City UniversityDublinIreland; School of Biotechnology, Dublin City UniversityDublinIreland.
Elaine W KayDepartment of Pathology Royal College of Surgeons in Ireland and Beaumont Hospital Dublin Ireland.
Gregor S KijankaBiomedical Diagnostics Institute, Dublin City University Dublin Ireland.
Dublin City University · IEBeaumont Hospital · IEGeorge Mason University · USRoyal College of Surgeons in Ireland · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ceramide synthase 5 is involved in the de novo synthesis of ceramide, a sphingolipid involved in cell death and proliferation. In this study, we investigated the role of ceramide synthase 5 in colorectal cancer by examining ceramide synthase 5 expression, clinico-pathological parameters and association with survival/death signalling pathways in cancer. Immunohistochemical analysis of CerS5 was performed on 102 colorectal cancer samples using tissue microarrays constructed from formalin-fixed and paraffin-embedded tissues. We found strong membranous ceramide synthase 5 staining in 57 of 102 (56%) colorectal cancers. A multivariate Cox regression analysis of ceramide synthase 5 expression adjusted for disease stage, differentiation and lymphovascular invasion revealed reduced 5-year overall survival (p = 0.001) and 5-year recurrence-free survival (p = 0.002), with hazard ratios of 4.712 and 4.322, respectively. The effect of ceramide synthase 5 expression on tumourigenic processes was further characterised by reverse phase protein array analysis. Reverse phase protein arrays were generated from laser capture microdissection-enriched carcinoma cells from 19 fresh-frozen colorectal cancer tissues. Measurements of phosphorylation and total levels of signalling proteins involved in apoptosis, autophagy and other cancer-related pathways revealed two distinct signalling networks; weak membranous ceramide synthase 5 intensity was associated with a proteomic network dominated by signalling proteins linked to apoptosis, whereas strong ceramide synthase 5 intensity was associated with a proteomic sub-network mostly composed of proteins linked to autophagy. In conclusion, high ceramide synthase 5 expression was found in colorectal cancer tissue and was associated with poorer patient outcomes. Our findings suggest that this may be mediated by a transition from apoptotic to autophagy signalling pathways in ceramide synthase 5 High expressing tumours, thus implicating ceramide synthase 5 in the progression of colorectal cancer.

Indexed as

apoptosisautophagyceramide synthase 5colorectal cancerlaser capture microdissectionprognosisreverse phase protein arrays

Identifiers

PMID27499893
PMCPMC4858121
OpenAlexW1587397837

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.